Skip to main content
Home
Issues
2023
June 2023 - Vol 16 No 1
2022
December - Vol 15 No 4
September - Vol 15 No 3
June - Vol 15 No 2
March - Vol 15 No 1 - Online Only
Issue Archive
Special Issues
December 2023 Vol 16, Payers' Guide to FDA Updates
Supplements
Special Issue Archive
Topics
Conference Correspondent
ESMO 2023 - Small Cell Lung Cancer
Web Exclusives
Web Exclusive Topics
All Web Exclusives
Select Drug Profiles
FDA Approvals
In the News
Press Releases
Videos
Interview with the Innovators
About
About AHDB
Contact Us
Permissions
Editorial Policies
Editorial Board
Editorial Process
Advertising Contacts
Advertising Policy
Reprints
Subscribe
Home
Issues
2023
June 2023 - Vol 16 No 1
2022
December - Vol 15 No 4
September - Vol 15 No 3
June - Vol 15 No 2
March - Vol 15 No 1 - Online Only
Issue Archive
Special Issues
December 2023 Vol 16, Payers' Guide to FDA Updates
Supplements
Special Issue Archive
Topics
Conference Correspondent
ESMO 2023 - Small Cell Lung Cancer
Web Exclusives
Web Exclusive Topics
All Web Exclusives
Select Drug Profiles
FDA Approvals
In the News
Press Releases
Videos
Interview with the Innovators
About
About AHDB
Contact Us
Permissions
Editorial Policies
Editorial Board
Editorial Process
Advertising Contacts
Advertising Policy
Reprints
Mark Knight
Authored Items
Initial Choice of TKI in Patients with CML Probably Not Important
Mark Knight
February 2013 Vol 6, No 1, Special Issue
in
Leukemia
Can Prognostic Factors Guide the Treatment of DLBCL?
Mark Knight
February 2013 Vol 6, No 1, Special Issue
Newly Discovered Genes in AML Can Identify Likely Response to Therapies
Mark Knight
February 2013 Vol 6, No 1, Special Issue
Molecular and Cytogenetic Assessments Infrequently Performed in Patients with CML Receiving First-Line Imatinib
Mark Knight
February 2013 Vol 6, No 1, Special Issue
in
Leukemia
Head-to-Head Comparison: Exenatide Outperforms Glimepiride in Controlling Glycemic Levels after Failing Metformin Therapy
Mark Knight
August 2012, Vol 5, No 5, Special Issue ADA 2012 Highlights
Head-to-Head Comparison: Exenatide Outperforms Glimepiride in Controlling Glycemic Levels after Failing Metformin Therapy
Mark Knight
Value-Based Care in Cardiometabolic Health August 2012, Vol 1, No 2
High OOP Costs for Medicare Patients with Cancer
Mark Knight
August 2012 Vol 5, No 5, Special Issue ASCO 2012 Payers' Perspective
Last modified: August 29, 2012